Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is of great interest to determine which biomarkers should be combined to ac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuroimage Clin
Main Authors: Ottoy, Julie, Niemantsverdriet, Ellis, Verhaeghe, Jeroen, De Roeck, Ellen, Struyfs, Hanne, Somers, Charisse, wyffels, Leonie, Ceyssens, Sarah, Van Mossevelde, Sara, Van den Bossche, Tobi, Van Broeckhoven, Christine, Ribbens, Annemie, Bjerke, Maria, Stroobants, Sigrid, Engelborghs, Sebastiaan, Staelens, Steven
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2019
Assuntos:
Regular Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444289/
https://ncbi.nlm.nih.gov/pubmed/30927601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nicl.2019.101771
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares